Cigna Group

The Cigna Group announced robust second quarter 2026 financial results, exceeding expectations and leading to an upward revision of its full-year earnings guidance.

The Cigna Group reaffirmed its projected full-year 2026 consolidated adjusted income from operations on a per share basis of at least $30.35.

The Cigna Group announced robust first-quarter 2026 results, with total revenues up 5% and adjusted income from operations increasing 12%, leading to an upward revision of its full-year earnings guidance.

The Cigna Group shareholders re-elected all twelve director nominees and ratified the appointment of PricewaterhouseCoopers LLP at the 2026 Annual Meeting.

The Cigna Group announced Brian C. Evanko will succeed David M. Cordani as CEO, effective July 1, 2026, while reaffirming its full-year 2026 financial outlook.

The Cigna Group reaffirms its projected full year 2026 consolidated adjusted income from operations of at least $30.25 per share.

The Cigna Group reported a 7% increase in total revenues to $71.7 billion for the second quarter of 2026, with net income rising 15% to $1.875 billion.

The Cigna Group reported a 5% increase in total revenues for the first quarter of 2026, driven by strong performance in its Evernorth Health Services segment.

The Cigna Group reported a significant increase in Q3 2025 shareholders' net income, driven by robust pharmacy revenues and the absence of prior year's equity impairment.

The Cigna Group announced an 11% increase in total revenues for the second quarter of 2025, reaching $67.18 billion, alongside a 5% rise in diluted earnings per share, despite a significant decline in operating cash flow.

The Cigna Group's Q1 2025 results show increased revenues and net income, driven by pharmacy and premium growth, and the completion of the Medicare Advantage divestiture to HCSC.

The Cigna Group's third-quarter results show a decrease in net income, impacted by a significant investment impairment, while adjusted income from operations saw a modest increase.

The Cigna Group announced a significant increase in 2025 net income and revenues, largely benefiting from the absence of prior-year impairments and strategic business optimization.

The Cigna Group's FY24 results reflect a year of growth and strategic realignment, highlighted by the pending sale of its Medicare Advantage business to HCSC.

The Cigna Group's recent 10-K filing outlines the company's capital structure, shareholder rights, and corporate governance practices.

Bryan Holgerson, See Remarks of Cigna Group, reported multiple transactions in common stock on July 9, 2026.

Nicole S Jones, See Remarks of Cigna Group, sold 2,677 shares of common stock on August 18, 2026 for $279.61 per share.

Nicole S Jones, See Remarks of Cigna Group, sold 19,436 shares of common stock on August 4, 2026 for $276.27 per share.

Cigna Group Chief Accounting Officer Jamie G. Kates exercised 899 stock options and subsequently sold the shares.

Cigna Group's EVP, Global CIO, Durga Prasad Koka, reported a transaction involving the withholding of shares for tax obligations.

Cigna Group Director George Kurian reported the acquisition of phantom stock units under the company's Deferred Compensation Plan.

The Cigna Group reports robust 2025 financial results, outlines strategic advancements, and announces a planned CEO succession for July 1, 2026.

The Cigna Group's 2025 Annual Meeting will be held virtually on April 23, 2025, and shareholders are encouraged to review proxy materials and vote on key proposals.

The Cigna Group reports strong revenue growth and strategic advancements in 2024, while addressing challenges in medical costs and setting future performance targets.

The Cigna Group is urging shareholders to vote on director elections, executive compensation, auditor ratification, and shareholder proposals at the upcoming annual meeting on April 24, 2024.

The Cigna Group is urging shareholders to vote on director elections, executive compensation, auditor ratification, and two shareholder proposals at the Annual Meeting on April 24, 2024.

The Cigna Group's 2024 Annual Meeting will be held virtually on April 24, 2024, with shareholders able to vote on key proposals including the election of directors and executive compensation.

Vanguard Capital Management disclosed a beneficial ownership of 19,814,433 shares, representing 7.51% of Cigna Group's common stock as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Cigna Group common stock following an internal realignment that disaggregated reporting responsibilities.

The Vanguard Group reported a 10.03% beneficial ownership in Cigna Group common stock, alongside an internal realignment affecting future reporting.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, disclosing a 4.0% beneficial ownership stake in The Cigna Group as of September 30, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 9.64% beneficial ownership stake in Cigna Group common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% of Cigna Corporation's common stock as of March 31, 2025.